Mental Health DailyResearch. Evidence. Perspective.Published research on vortioxetine.
The RELIEVE study provides pivotal insights into the effectiveness of vortioxetine in treating patients with Major Depressive Disorder (MDD) co-morbid with Generalized Anxiety Disorder (GAD)…
Read articleTrintellix (Vortioxetine hydrobromide), formerly sold under the name Brintellix, is an antidepressant that was jointly developed by the pharmaceutical companies Lundbeck and Takeda. In 2013,…
Read articleBrintellix (Vortioxetine) is an atypical antidepressant manufactured by Lundbeck and Takeda. It was approved by the FDA in 2013 for the treatment of major depressive disorder, but failed to …
Read articleBrintellix (Vortioxetine) is considered an atypical antidepressant that was co-developed by pharmaceutical companies Lundbeck and Takeda. Most consider Brintellix to be a new antidepressant …
Read articleBrintellix (Vortioxetine) is a drug that was approved by the FDA in 2013 to treat major depression. It is regarded as an atypical antidepressant, meaning that it’s mechanisms of action are u…
Read article